Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first-line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving remission in 60%–80% of cases. For the remaining 20%–40% of patients there is an urgent need to identify early biomarkers of resistance to rituximab to adapt therapeutic management. In nephrotic patients, rituximab is found in the blood more transiently than in other autoimmune diseases without proteinuria, due to rituximab wasting in the urine. However, rituximab immunomonitoring is not routinely performed. We evaluated the predictive value of serum rituximab levels in patients with pMN three months after rituximab injection (month-3) on clinical remission rates six months (month-6) and 12 months (month-12) after injection and investigated predictive factors for serum rituximab levels at month-3. Sixty-eight patients treated with rituximab between July 2015 and January 2020 from two French nephrology centers were included. We identified residual rituximab levels at month-3 as a novel early predictor of remission at month-6 (p < 0.0001) and month-12 (p = 0.001). Reduced likelihood of remission in patients with undetectable rituximab at month-3 was associated with lower serum albumin and higher anti-PLA2R titers at baseline and with lower serum albumin, higher proteinuria, higher CD19+ counts and higher anti-PLA2R titers during follow-up. In multivariate analysis, high baseline proteinuria and undetectable rituximab levels at month-3 were independent risk factors for treatment failure at month-6 and high baseline weight and undetectable rituximab levels at month-3 were independent risk factors for treatment failure at month-12. We identified serum albumin at baseline as a predictive factor for serum rituximab levels at month-3. Patients with serum albumin below 22.5 g/L at baseline had an 8.66-fold higher risk of having undetectable rituximab levels at month-3. Therefore, rituximab immunomonitoring in pMN patients treated with rituximab would allow the detection of patients at risk of treatment failure as early as month-3. Studies are needed to
assess whether patients with low residual rituximab levels at month-3 may benefit from an early additional course of rituximab.

**Keywords:** membranous nephropathy, nephrotic syndrome, autoimmunity, rituximab, chronic kidney disease rituximab immunomonitoring in membranous nephropathy

**INTRODUCTION**

Primary membranous nephropathy (pMN) is an autoimmune disease affecting kidney glomerulus and the most common cause of nephrotic syndrome (NS) in non-diabetic adults. The course of the disease is highly variable, ranging from spontaneous remission to progressive chronic kidney disease. Histologically, pMN is characterized by subepithelial immune deposits containing immunoglobulins G (IgG) and complement fractions resulting in thickening of the glomerular basement membrane and the formation of spikes (1). The pathophysiology of pMN involves autoantibodies targeting podocyte proteins such as M-type phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type-1 domain-containing 7A (THSD7A) in 70%–80% and 3%–5% of patients, respectively (2, 5). Immune complex deposits are responsible for the activation of the complement cascade and podocyte damage (4–6). The pathogenicity of anti-PLA2R1 and anti-THSD7A autoantibodies has been demonstrated in vitro and in vivo (4, 7, 8). The recognition of pMN as an autoantibody-mediated disease has promoted the use of immunosuppressive drugs. Rituximab – a chimeric monoclonal antibody targeting CD20 – can trigger B cell death by apoptosis, complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity leading to an elimination of autoantibodies (9–11). Rituximab was first developed for the treatment of hematological malignancies, but is now used to treat many immune-mediated diseases (12). Rituximab is progressively becoming a first line therapy for pMN patients with proven safety and efficacy, achieving remission in 60%–80% of patients (13–15). However, for the remaining 20%–40% of patients there is an urgent need to identify early biomarkers of resistance to rituximab in order to adapt therapeutic management. Some patients with pMN may develop anti-rituximab antibodies that may decrease the effectiveness of the treatment (16). In these cases obinutuzumab and ofatumumab have been shown to be effective (17–20). Other patients are undertreated because of the highly variable bioavailability of rituximab in nephrotic patients (21). In nephrotic patients, rituximab – which binds to albumin – can be eliminated in the urine, thus rituximab is found in the blood more transiently than in other autoimmune diseases treated with rituximab without proteinuria (21, 22). There is still uncertainty about which rituximab protocol to use in nephrotic patients. Patients with the shortest exposure to rituximab could benefit from additional courses of rituximab to increase their likelihood of clinical remission. However, rituximab immunomonitoring is not yet routinely performed in patients with pMN.

The aims of this study were: (i) to evaluate the predictive value of serum rituximab levels in patients with pMN three months after rituximab injection (month-3) on clinical remission rates six months (month-6) and 12 months (month-12) after rituximab injection and (ii) to establish predictive factors for undetectable serum rituximab levels at month-3.

**MATERIAL AND METHODS**

**Study Participants**

Sixty-eight patients with pMN from a prospective cohort were included (NCT02199145). Patients were enrolled from two French nephrology centers from July 2015 to January 2020. The inclusion criteria were (1) biopsy-proven diagnosis of membranous nephropathy; (2) primary membranous nephropathy defined by the absence of concomitant autoimmune disease, negative hepatitis B and C serologies, and negative cancer workup; (3) rituximab treatment with two 1 g infusions two weeks apart; and (4) serum samples available at month-3. Patients should not receive any other immunosuppressive therapy at the same time as rituximab. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the appropriate institutional review committee. Written informed consent was obtained from participants prior to inclusion in the study.

**Outcome**

Clinical remission was evaluated at month-6 and month-12. Clinical remission was defined according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (23). Complete remission was defined by a urinary protein-to-creatinine ratio < 0.3 g/d, accompanied by a normal serum albumin concentration and a preserved kidney function. Partial remission was defined by urinary protein-to-creatinine ratio < 3.5 g/d with 50% reduction of proteinuria, accompanied by an improvement or normalization of the serum albumin concentration and preserved kidney function. Treatment failure was defined by the lack of clinical remission.

**Detection of Anti-PLA2R1 and Anti-THSD7A Antibodies**

Serum levels of total IgG anti-PLA2R1 antibodies were measured by the ELISA test developed by EUROIMMUN (Medizinische Labordiagnostika AG, Lübeck, Germany). Participants were considered as anti-PLA2R1–positive when levels were >14 RU/mL. Total IgG anti-THSD7A antibodies were measured by the indirect immunofluorescence test developed by EUROIMMUN (Medizinische Labordiagnostika AG, Lübeck, Germany).

**Rituximab Immunomonitoring by ELISA**

Serum levels of rituximab were measured by ELISA according to the manufacturer’s instructions (LISA-TRACKER Duo Rituximab; Theradiag, Croissy Beaubourg, France). This assay measures only free rituximab. The limit of detection defined by
the manufacturer was 2 µg/mL. Rituximab levels were measured 3 months after the last infusion. This time interval was chosen based on a previous bioavailability study (21).

**Anti-Rituximab Antibodies Detection**

Anti-rituximab antibodies were detected by ELISA (LISA-TRACKER, Theradiag, Croissy Beaubourg, France). The limit of detection for anti-rituximab antibodies defined by the manufacturer was 5 ng/mL.

**Statistical Analyses**

Categorical data were described as frequency and percentage and were compared using Fisher’s exact test. Quantitative data were described as median and interquartile range and were compared using Wilcoxon-Mann-Whitney test. Survival curves were assessed by the Kaplan-Meier method and compared with the log-rank test. A P-value < 0.1 was used to select variables that were entered into a single multivariate logistic model with backward selection (threshold = 0.05). We performed a receiver operating characteristic curve (ROC) analysis to assess the optimal threshold of predictive factors identified in multivariate analysis that could predict the risk of undetectable rituximab levels at month-3. A P-value < 0.05 indicated statistical significance. Statistical analyses were performed using GraphPad Prism 8.4.3 (GraphPad Software Inc., San Diego, CA) and SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC).

**RESULTS**

**Population Characteristics**

Sixty-eight patients with pMN treated with rituximab (two 1 g infusions two weeks apart) were included. A supportive therapy with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was consistently associated with rituximab. Table 1 shows the characteristics of the study cohort at baseline (i.e. the day of rituximab injection) and during follow-up.

Serum rituximab levels were measured at month-3. In 38 patients (56%), rituximab was undetectable in the serum (i.e. < 2 µg/mL) at month-3. In 30 patients (44%), serum rituximab was over 2 µg/mL at month-3. At baseline, in patients with undetectable serum rituximab levels at month-3, anti-PLA2R1 titers were higher and serum albumin levels were lower than in patients with serum rituximab levels > 2 µg/mL at month-3 (Table 1). Proteinuria tended to be higher in patients with undetectable serum rituximab levels at month-3, although this did not reach statistical significance (Table 1). All other baseline characteristics were similar, including age, gender, weight, type of autoantibodies, serum creatinine levels and CD19+ cell counts.

During follow-up in patients with undetectable serum rituximab levels at month-3, anti-PLA2R1 titers were higher at month-3 and month-6; proteinuria was higher at month-3 and month-6; and serum albumin levels were lower at month-3 and month-6 than in patients with serum rituximab levels > 2 µg/mL at month-3 (Table 1). B cells re-emerged more quickly in patients with undetectable serum rituximab levels at month-3 than in patients with serum rituximab levels > 2 µg/mL at month-3 (Table 1).

Anti-rituximab antibodies were never detected at month-3, and were detected at month-6 in 4 of 38 patients (11%) with undetectable serum rituximab levels at month-3 and 2 of 30 patients (7%) with serum rituximab levels > 2 µg/mL at month-3 (Table 1).

**Outcome**

Clinical remission was analyzed at month-6 and month-12. Clinical remission (partial or complete) was obtained in 36 of 68 patients (53%) at month-6 and in 41 of 68 patients (60%) at month-12 (Table 1). Serum rituximab levels at month-3 were significantly lower in patients who failed to achieve clinical remission at month-6 (0.06 µg/mL [IQR, 0.1–1.1] versus 3.2 µg/mL [IQR, 0.9–11.0]; p < 0.0001) and at month-12 (0.1 µg/mL [IQR, 0.0–1.2] versus 2.3 µg/mL [IQR 0.4–9.0]; p = 0.0004) (Figures 1A, B). Patients with serum rituximab levels > 2 µg/mL at month-3 achieved clinical remission more frequently at month-6 and month-12 than patients with undetectable serum rituximab levels at month-3 (Table 1). Kaplan–Meier analysis demonstrates faster time to clinical remission when serum rituximab levels are over 2 µg/mL at month-3 (Figure 1C).

Regarding cases who developed anti-rituximab antibodies, 4 of 6 patients (67%) did not achieve clinical remission at either month-6 or month-12. Two patients with anti-rituximab antibodies (1 with undetectable serum rituximab at month-3 and 1 with serum rituximab > 2 µg/mL at month-3) achieved partial clinical remission at month-6.

We then investigated the impact of rituximab levels on clinical outcome in patients with severe nephrotic syndrome, i.e. with baseline proteinuria exceeding the median value (6 g/d). Among these patients, 20 patients had undetectable rituximab levels at month-3 and 14 patients had rituximab levels > 2 µg/mL at month-3. Patients with serum rituximab levels > 2 µg/mL at month-3 achieved clinical remission more frequently at month-6 and month-12 than patients with undetectable serum rituximab
Characteristics at baseline

We observed that rituximab underdosing is not uncommon, with undetectable serum rituximab levels at month-3 in patients with pMN on clinical characteristics at month-6 and month-12 after rituximab injection. Undetectable serum rituximab levels at month-3 were also associated with lower clinical remission rates at month-6 and month-12 and with a longer time to achieve clinical remission. Undetectable serum rituximab levels at month-3 were also associated with higher PLA2R1 titers and lower serum albumin levels at baseline and with higher PLA2R1 titers, higher proteinuria, higher CD19\(^+\) counts and lower serum albumin levels at month-3 associated with higher PLA2R1 titers and lower serum albumin levels at month-3 (HR, 0.89; 95% CI, 0.82–0.97; \(p = 0.005\)) (Table 4). Using ROC curves, we determined a threshold of albuminemia at baseline of 22.5 g/L that was associated with the risk of having an undetectable serum rituximab level at month-3 (at month-6: 64% versus 30%, \(p = 0.002\)) and at month-12 and with a longer time to achieve clinical remission. This is consistent with our previous results showing that higher residual serum rituximab concentrations at month-3 were significantly correlated with higher B cell depletion and lower requirement for repeat doses of rituximab (21).

The second aim of this study was to identify factors associated with undetectable serum rituximab levels at month-3. Little attention has been paid to rituximab pharmacokinetics in nephrotic patients. Antibodies – including rituximab – interact with the neonatal Fc receptor for IgG (FcRn) present on epithelial cells, endothelial cells, monocytes and/or macrophages, and dendritic cells (24). FcRn protects antibodies from degradation by lysosomes and thus reduces antibody clearance by allowing recycling into the cellular environment (25, 26). However, despite

---

**Table 1** Characterization of patients at baseline (i.e. the day of rituximab injection) and during follow-up.

| Variables | All patients (n = 68) | Patients with serum rituximab level < 2µg/mL at month-3 (n = 38) | Patients with serum rituximab level > 2µg/mL at month-3 (n = 30) | P-value |
|-----------|----------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------|
| Characteristics at baseline | Age (years) | 58.5 [49.0–67.2] | 57.5 [44.0–67.5] | 60.5 [50.5–68.0] | 0.3 |
| Gender (Female/Male) | 19/49 | 14/24 | 5/25 | 1 |
| Weight (kg) | 76.6 [67.4–84.0] | 76.3 [66.6–93.6] | 77.0 [67.9–86.0] | 1 |
| Serum creatinine (µmol/L) | 1.20 [0.87–1.51] | 1.19 [0.83–1.38] | 1.37 [0.90–1.83] | 0.07 |
| Serum albumin (g/L) | 22.6 [16.0–29.0] | 20.2 [14.1–24.6] | 26.6 [22.0–31.7] | 0.001 |
| CD19\(^+\) count (cell/µL) | 186.5 [123.5–270.0] | 208.0 [138.0–280.0] | 142.5 [77.2–215.5] | 0.2 |
| Anti-PLA2R1 Ab titer (RU/mL) | 149 [57–303] | 184 [71–488] | 89 [20–173] | 0.01 |
| Patients with anti-RTX Ab | 6 (9%) | 4 (11%) | 2 (7%) | 0.7 |
| Characteristics at month-6 | Age (years) | 58.5 [49.0–67.2] | 57.5 [44.0–67.5] | 60.5 [50.5–68.0] | 0.3 |
| Gender (Female/Male) | 19/49 | 14/24 | 5/25 | 1 |
| Weight (kg) | 76.6 [67.4–84.0] | 76.3 [66.6–93.6] | 77.0 [67.9–86.0] | 1 |
| Serum creatinine (µmol/L) | 1.20 [0.87–1.51] | 1.19 [0.83–1.38] | 1.37 [0.90–1.83] | 0.07 |
| Serum albumin (g/L) | 22.6 [16.0–29.0] | 20.2 [14.1–24.6] | 26.6 [22.0–31.7] | 0.001 |
| CD19\(^+\) count (cell/µL) | 186.5 [123.5–270.0] | 208.0 [138.0–280.0] | 142.5 [77.2–215.5] | 0.2 |
| Anti-PLA2R1 Ab titer (RU/mL) | 149 [57–303] | 184 [71–488] | 89 [20–173] | 0.01 |
| Patients with anti-RTX Ab | 6 (9%) | 4 (11%) | 2 (7%) | 0.7 |

**DISCUSSION**

The first aim of this study was to evaluate the predictive value of serum rituximab levels at month-3 in patients with pMN on clinical remission rates at month-6 and month-12 after rituximab injection. We observed that rituximab underdosing is not uncommon, with 56% of patients having undetectable serum rituximab levels at month-3. Undetectable serum rituximab levels at month-3 were associated with lower clinical remission rates at month-6 and month-12 and with a longer time to achieve clinical remission. Undetectable serum rituximab levels at month-3 were also associated with higher PLA2R1 titers and lower serum albumin levels at baseline and with higher PLA2R1 titers, higher proteinuria, higher CD19\(^+\) counts and lower serum albumin levels at month-3 and month-6. These results suggest that patients with severe NS have a shorter exposure to rituximab – likely due to rituximab wasting in the urine – compared to patients with a mild NS or without NS, leading to a decrease in the effectiveness of B cell depletion and therefore to a higher rate of treatment failure. This is consistent with our previous results showing that higher residual serum rituximab concentrations at month-3 were significantly correlated with higher B cell depletion and lower requirement for repeat doses of rituximab (21).
rituximab recycling, nephrotic patients have a shorter exposure to rituximab compared to a population without proteinuria, due to the clearance of rituximab in the urine (22). Fervenza et al. have demonstrated a shorter rituximab half-life in patients with pMN compared to patients with rheumatoid arthritis (11.5 days versus 18.0 days) treated with four doses of 375 mg/m² (day 1, day 8, day 15, and day 22) (15). More recently, we have shown that residual rituximab levels at month-3 were significantly lower in patients with pMN compared to myasthenia gravis patients matched for age, gender and weight and treated

**FIGURE 1** | (A) Serum rituximab (RTX) levels at month-3 (M3) according to clinical status at month-6 (M6). (B) Serum rituximab (RTX) levels at month-3 (M3) according to clinical status at month-12 (M12). (C) Time from initiation of rituximab treatment to remission of nephrotic syndrome according to serum rituximab levels at month-3. M3, month-3 after rituximab injection; M6, month-6 after rituximab injection; M12, month-12 after rituximab injection; RTX, rituximab; UP, 24-hour urinary protein excretion.

**TABLE 2** | Univariate and multivariate analysis of variables associated with clinical remission at month-6.

| Variables | Remission at month-6 (n=36) | No remission at month-6 (n=32) | Univariate P-value | Multivariate P-value |
|-----------|-----------------------------|--------------------------------|-------------------|----------------------|
| Age (years) | 58.0 [46.0–67.7] | 58.5 [49.2–67.7] | 0.7 | |
| Gender (Female/Male) | 9/27 | 10/22 | 0.6 | |
| Weight (kg) at baseline* | 74.3 [66.0–82.0] | 77.3 [70.7–89.6] | 0.1 | |
| UP (g/d) at baseline* | 5.0 [4.0–7.0] | 7.8 [5.8–12.2] | 0.0001 | 0.02 |
| Serum creatinine (µmol/L) at baseline | 119 [86–151] | 121 [87–163] | 0.7 | |
| Serum albumin (g/L) at baseline* | 25.3 [20.7–30.2] | 26.6 [21.5–33.0] | <0.0001 | 0.8 |
| CD19+ count (cell/µL) at baseline | 158.5 [112.8–277.5] | 208.0 [122.0–291.0] | 0.3 | |
| CD19+ count (cell/µL) at month-3* | 0.0 [0.0–2.7] | 3.0 [1.0–25.0] | 0.002 | 0.3 |
| Etiology | | | | 0.2 |
| Anti-PLA2R1-associated pMN | 33 (92%) | 29 (91%) | | |
| Anti-THSD7A-associated pMN | 0 (0%) | 2 (6%) | | |
| Double negative patients | 3 (8%) | 1 (3%) | | |
| Anti-PLA2R1 Ab titer (RU/mL) at baseline* | 89 [21–173] | 218 [76–661] | 0.002 | 0.9 |
| Patient with RTX <2µg/mL at month-3* | 12 (33%) | 26 (81%) | <0.0001 | 0.007 |

*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.

Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; RTX, rituximab; UP, 24-hour urinary protein excretion.
### TABLE 3 | Univariate and multivariate analysis of variables associated with clinical remission at month-12.

| Variables | Remission at month-12 (n=41) | No remission at month-12 (n=27) | Univariate P-value | Multivariate P-value |
|-----------|-----------------------------|-------------------------------|-------------------|---------------------|
| Age (years) | 60.0 [50.0–68.0] | 56.0 [42.0–67.0] | 0.3 | |
| Gender (Female/Male) | 11/30 | 8/19 | 1 | |
| Weight (kg) at baseline* | 71.5 [66.0–82.0] | 78.0 [74.0–89.2] | 0.06 | 0.02 |
| UP (g/d) at baseline* | 5.2 [4.0–7.1] | 7.4 [5.6–11.9] | 0.005 | 0.2 |
| Serum creatinine (µmol/L) at baseline | 118 [97–149] | 123 [87–184] | 0.4 | |
| Serum albumin (g/L) at baseline* | 24.8 [20.2–29.4] | 16.0 [13.0–22.1] | 0.001 | 0.7 |
| CD19+ count (cell/µL) at baseline | 186.0 [125.0–280.0] | 185.0 [88.7–263.8] | 0.9 | |
| CD19+ count (cell/µL) at month-3* | 0.0 [0.0–2.7] | 3.0 [1.0–16.0] | 0.005 | 0.9 |
| Etiology | | | | |
| Anti-PLA2R1-associated pMN | 37 (90%) | 25 (93%) | | |
| Anti-THSD7A-associated pMN | 1 (2%) | 1 (3%) | | |
| Double negative patients | 3 (8%) | 1 (3%) | | |
| Anti-PLA2R1 Ab titer (RU/mL) at baseline* | 86 [21–188] | 226 [110–561] | 0.001 | 0.5 |
| Patient with RTX <2µg/mL at month-3* | 16 (26%) | 22 (85%) | 0.001 | 0.01 |

*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.

Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; RTX, rituximab; UP, 24-hour urinary protein excretion.

### TABLE 4 | Univariate and multivariate analysis of variables associated with serum rituximab levels at month-3.

| Variables | Patients with serum rituximab level < 2µg/mL at month-3 (n = 38) | Patients with serum rituximab level > 2µg/mL at month-3 (n = 30) | Univariate P-value | Multivariate P-value |
|-----------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------|---------------------|
| Characteristics at baseline | | | | |
| Age (years) | 57.5 [44.0–67.5] | 60.5 [50.5–68.0] | 0.3 | |
| Gender (Female/Male)* | 14/24 | 5/25 | 0.1 | 0.3 |
| Weight (kg) | 76.3 [66.6–83.6] | 77.0 [67.9–86.0] | 1 | |
| UP (g/d)* | 7.0 [4.9–10.1] | 5.5 [3.9–7.1] | 0.07 | 0.2 |
| Serum creatinine (µmol/L)* | 119 [93–198] | 137 [90–183] | 0.1 | |
| Serum albumin (g/L)* | 20.2 [14.1–24.6] | 26.6 [22.0–31.7] | 0.001 | 0.005 |
| CD19+ count (cell/µL)* | 208.0 [138.0–280.0] | 142.5 [77.2–215.6] | 0.2 | |
| Etiology | | | | |
| Anti-PLA2R1-associated pMN | 35 (92%) | 27 (90%) | | |
| Anti-THSD7A-associated pMN | 0 (0%) | 2 (7%) | | |
| Double negative patients | 3 (8%) | 1 (3%) | | |
| Anti-PLA2R1 Ab titer (RU/mL)* | 184 [71–489] | 89 [20–173] | 0.01 | 0.5 |

*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.

Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; RTX, rituximab; UP, 24-hour urinary protein excretion.

### FIGURE 2 | Flow chart of patients included in this study and outcome according to serum rituximab levels at month-3. M3, month-3 after rituximab injection; M6, month-6 after rituximab injection; RTX, rituximab; UP, 24-hour urinary protein excretion.
with a similar treatment regimen (21). In addition to urinary excretion of rituximab, internalization and destruction of rituximab by target B cells (27, 28) and anti-rituximab antibodies (16, 20) may also contribute to decreased residual rituximab levels. Here, we identified baseline serum albumin level as a predictive factor for residual serum rituximab levels at month 3. Patients with severe NS and especially with serum albumin below 22.5 g/L at baseline were more likely to have an undetectable serum rituximab level at month-3. Previously, we have shown that a high-dose rituximab protocol (two perfusions of 1 g two weeks apart) was more effective than a low-dose rituximab protocol (two perfusions of 375 mg/m² one week apart) in achieving clinical remission at month-6 in patients with pMN (29). The median residual rituximab level at month-3 was also higher with the high-dose rituximab protocol (29). Our present results suggest that this regimen of rituximab may still be insufficient in patients with severe NS. It has recently been shown that reinfusion of rituximab can induce remission in patients considered refractory to rituximab (20, 30). Therefore, the management of pMN patients treated with rituximab should be individually adjusted by rituximab immunomonitoring. For patients with undetectable serum rituximab levels at month-3 and active NS, additional rituximab injections should be planned and supportive therapy optimized to obtain higher serum rituximab levels and thereby increase the likelihood of remission and reduce time with active NS. Additional doses of rituximab should be considered as early as month-3 in patients with proteinuria greater than 5.5 g/d at month-3 as we have shown that these patients never achieve remission at month-6. However, it seems acceptable to wait until month-6 for patients with proteinuria between 3.5 g/d and 5.5 g/d at month-3 as we have shown that 33% of these patients achieve remission at month-6. The addition of a calcineurin inhibitor (CNI) to rituximab could also be discussed (31). In addition to their immunosuppressive effect, CNIs may decrease the urinary loss of rituximab by causing afferent and efferent glomerular arteriolar vasoconstriction. However, this combination is likely to result in enhanced immunosuppression with concomitant adverse events.

Recently, a study has shown that rituximab was less effective than cyclophosphamide in inducing immunological remission in patients with the highest anti-PLA2R1 titers (32). However, patients with the highest anti-PLA2R1 titers were more likely to have severe NS and thus more likely to be underdosed in rituximab (33–35). In these patients, a personalized management based on the rituximab immunomonitoring at month-3 may increase the effectiveness of rituximab and thus be as effective as cyclophosphamide but with less toxicity.

This study has several limitations. First, it is a retrospective analysis of a prospective cohort but we used systematically collected prospective data and samples. Second, the number of participants is relatively small. Third, patients with undetectable serum rituximab levels at month-3 had more severe disease at baseline, which may suggest that initial disease severity may contribute to their worse outcome. However, in multivariate analysis, an undetectable serum rituximab level at month-3 was an independent risk factor for treatment failure at months 6 and 12. Furthermore, by comparing the outcome of patients with detectable or undetectable rituximab levels in the group of patients with baseline proteinuria > 6.0 g/d – these patients are expected to have a similarly severe nephrotic syndrome – we demonstrated that rituximab levels were still predictive of clinical remission at months 6 and 12. Thus, these results show that rituximab levels at month-3 are predictive of clinical remission, regardless of the initial severity of the disease.

To conclude, in pMN patients treated with rituximab, rituximab immunomonitoring at month-3 might be a useful biomarker to adapt therapeutic management in addition to CD19+ cell count monitoring, anti-rituximab antibodies monitoring (16, 20), anti-PLA2R1 antibody titer (36) and PLA2R1 epitope spreading (37). Personalized management may increase the efficacy of rituximab in patients with severe NS and may dispense the use of cyclophosphamide. Prospective studies are needed to compare the personalized management of patients with pMN based on rituximab immunomonitoring to conventional management.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by NCT02199145. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

BS-P and VB provided the research idea and study design. MT, VB, BS-P, and KZ analyzed and interpreted the data. BS-P, VE, TC, MC, and SB-S provided medical oversight. VB and SB performed rituximab measurement and anti-rituximab antibody detection. MT, BS-P, and VB drafted and revised the manuscript. BS-P and VB contributed equally to this work. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was academic, funded by Nice University Hospital.

**REFERENCES**

1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN (2017) 12(6):983–97. doi: 10.2215/CJN.11761116

2. Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. N Engl J Med (2009) 361(1):11–21. doi: 10.1056/NEJMoa0810457
17. Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is Effective for the Treatment of Rituximab-Resistant Membranous Nephropathy. *J Immunol Res* (2019) 2019:1324804. doi: 10.1155/2019/1324804

18. Klomjit N, Fervenza FC, Zand L. Successful Treatment of Patients With Refractory Membranous Nephropathy. *Clin J Am Soc Nephrol* CJASN (2011) 6(6):1286–91. doi: 10.2215/CJN.05080610

19. Fervenza FC, Abraham RS, Erickson SB, Cremin DJ, Brglez V, Zorzi K, Dolla G, et al. Anti-PLA2R Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation. *J Immunol Res* (2019) 2019:1324804. doi: 10.1155/2019/1324804

20. Teisseyre M, Boyer-Suavet S, Seitz-Polski B. Compartment Pathways in Membranous Nephropathy: Complex and Multifactorial. *Kidney Int Rep* (2020) 5(5):572–4. doi: 10.1016/j.ekir.2020.02.1033

21. Ronco P, Debiec H. Molecular Pathogenesis of Membranous Nephropathy. *Annu Rev Pathol* (2019) 15:287–313. doi: 10.1146/annurev-pathol-020117-043811

22. Tomas NM, Hoxha E, Reinicke AT, Fester L, Helmschen U, Gerth J, et al. Anti-autoantibodies Against Thrombospondin Type 1 Domain-Containing 7A Induce Membranous Nephropathy. *J Clin Invest* (2016) 126(7):2519–32. doi: 10.1172/JCI85265

23. Meyer-Schwesinger C, Tomas NM, Dehde S, Seifert L, Hermans-Borgmeyer I, Reinicke AT, et al. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy. *Kidney Int* (2020) 97(5):913–9. doi: 10.1016/j.kint.2019.10.022

24. Manches O, Liu G, Chaperot L, Gressin R, Molens J-P, Jacob M-C, et al. In Vitro Mechanisms of Action of Rituximab on Primary Non-Hodgkin Lymphomas. *Blood* (2003) 101(3):949–54. doi: 10.1182/blood-2002-02-0469

25. Brglez V, Boyer-Suavet S, Seitz-Polski B. Complement Pathways in Membranous Nephropathy: Historical and Future Perspectives. *Haematologica* (2010) 95(1):135–43. doi: 10.3324/haematol.2008.001628

26. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for Idiopathic Membranous Nephropathy: A 2-Year Study. *N Engl J Med* (2007) 357(25):2477–87. doi: 10.1056/NEJMoa0703945

27. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, et al. Fc Gamma Receptor IIb on Target B Cells Promotes Rituximab Internalization and Reduces Clinical Efficacy. *Blood* (2011) 118(9):2530–40. doi: 10.1182/blood-2011-01-330357

28. Reddy V, Cambridge G, Isenben DA, Glennie MJ, Cragg MS, Leandro M. Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus. *Arthritis Rheumatol Holboken NJ* (2015) 67(8):2046–55. doi: 10.1002/art.39167

29. Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zagrini C, et al. High-Dose Rituximab and Early Remission in PLA2R-Related Membranous Nephropathy. *Clin J Am Soc Nephrol* CJASN (2019) 14(8):1173–82. doi: 10.2215/CJN.1179018

30. Dahan K, Johannet C, Esteve E, Plaisier E, Debiec H, Ronco P. Retreatment With Rituximab for Membranous Nephropathy With Persistently Elevated Titers of Anti-Phospholipase A2 Receptor Antibody. *Kidney Int* (2019) 95(4):233–44. doi: 10.1016/j.kint.2018.10.021

31. Waldman M, Beck LH, Braun M, Wilkins K, Balow JE, Austin HA. Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab. *Kidney Int Rep* (2016) 1(2):73–84. doi: 10.1016/j.ekir.2016.05.002

32. Van de Logt A-E, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, et al. Immunological Remission in PLA2R-Antibody-Associated Membranous Nephropathy: Cyclophosphamide versus Rituximab. *Kidney Int* (2018) 93(4):1016–7. doi: 10.1016/j.kint.2017.12.019

33. Hofstra JM, Beck LH, Beck DM, Wetzels JF, Salant DJ. Anti-Phospholipase A2 Receptor Antibodies Correlate With Clinical Status in Idiopathic Membranous Nephropathy. *Clin J Am Soc Nephrol* CJASN (2011) 6(6):1286–91. doi: 10.2215/CJN.07208010

34. Hofstra JM, Debiec H, Short CD, Pellel T, Kleta R, Mathiesen PW, et al. Anti-Phospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy. *J Am Soc Nephrol* JASN (2012) 23(10):1735–43. doi: 10.1681/ASN.2012030242

35. Jullien P, Seitz Polski B, Maillard N, Thibaudin D, Laurent B, Ollier E, et al. Anti-Phospholipase A2 Receptor Antibody Levels at Diagnosis Predicts Spontaneous Remission of Idiopathic Membranous Nephropathy. *Clin Kidney J* (2017) 10(2):209–14. doi: 10.1093/ckj/fsx012

36. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for Membranous Nephropathy With Persistently Elevated Titers of Anti-Phospholipase A2 Receptor Antibody. *Kidney Int* (2010) 77(8):1177–85. doi: 10.1038/ni.2155

37. Brglez V, Boyer-Suavet S, Cremin DJ, Brglez V, Zorzi K, Dolla G, et al. Analysis and Management of Rituximab Resistance in PLA2R-Associated Membranous Nephropathy. *Kidney Int Rep* (2021) 6(4):1183–8. doi: 10.1016/j.ekir.2021.01.022

38. Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, et al. Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients With Severe Membranous Nephropathy: Preliminary Findings With Double Filtration Plasmapheresis and Ofatumumab. *Nephron* (2020) 144(1):30–5. doi: 10.1159/000501888

39. Teisseyre M, Boyer-Suavet S, Crémont M, Brglez V, Essault V, Seitz-Polski B. Rituximab Bioavailability in Primary Membranous Nephropathy. *Nephrol Dial Transplant* (2019) 34(1):423–5. doi: 10.1093/ndt/gfy041

40. Jacobs R, Langer-Jacob T, Duong M, Stahl K, Haller H, Schmidt RE, et al. Detection and Quantification of Rituximab in the Human Urine. *J Immunol Methods* (2017) 451–81. doi: 10.1016/j.jim.2017.09.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Teisseyre, Cremoni, Boyer-Suavet, Crepin, Benzaken, Zorzi, Essault, Brglez and Seitz-Polski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.